Cooperative Agreement U01DA063352
Award Date 9/15/25
Completion Date 7/31/28
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $305,369 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Taesun, LLC in Colorado. The grant, with a period of performance from August 1, 2025 to January 31, 2026, is for the development of a comprehensive device that integrates fentanyl test strips with sample preparation features to enable convenient and discreet fentanyl testing in high-risk environments....
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a 5-year Project Grant of $184,706 to the University of North Carolina at Chapel Hill (UNC-CH) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will fund research to investigate the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala, a key component of the stress response. Specifically, the project will develop a mouse model of...
- This federal Project Grant award of $457,701 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to understand the pharmacodynamics of combined methamphetamine and fentanyl use. The primary objectives are to: 1) elucidate the mechanisms underlying polysubstance use disorders involving stimulants and opioids, and 2) investigate the role of the hypocretin/orexin neuropeptide system as a potential target for...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $2,923,842 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Atai Therapeutics, Inc. (UEI: TE66JYGMACX5) on August 15, 2025. The funding supports the optimization and development of non-hallucinogenic 5-HT2A/2C agonists as potential therapeutics for opioid use disorder (OUD). The project aims to leverage the therapeutic potential of psychedelics while...
- This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $889,713 to The Ohio State University from April 2021 through March 2023. The funding supports research to develop dual-cavity baskets assembled into nanoparticles as nano-antidotes for overdose with fentanyl and its derivatives. Specifically, the awardee will functionalize dual-cavity baskets with biocompatible groups to trap...
- This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $3,287,052 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Virogenomics Biodevelopment, Inc., a woman-owned small business in Tigard, Oregon. The award, granted in May 2025, is funding IND-enabling studies and Phase I clinical trials to advance DRHQ, a novel immunotherapeutic compound developed by Virogenomics to treat methamphetamine use disorder. The research...
- The National Institute on Drug Abuse (NIDA) awarded a $220,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Amalgent Therapeutics, Inc. in Greenville, NC. This grant supports the development of a novel opioid adjuvant technology that aims to enhance the pain-relieving efficacy of opioid medications while mitigating risks such as abuse potential, tolerance, and neuropathic pain. The project has two key objectives: 1) investigating the mechanism by which the...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $386,452 to Electronic Biosciences, Inc. to develop rapid fingerstick diagnostics for opioid and stimulant use disorders. The award period is from April 1, 2025 to March 31, 2026. The project aims to address the escalating public health crisis of opioid and stimulant use disorders, which have contributed to over 107,000 overdose deaths in the...